[1] Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view[J]. Cell, 2012, 148: 1258-1270.
[2] Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, Guzzetta KE, Jaggar M, Long - Smith CM, Lyte JM, Martin JA, Molinero-Perez A, Moloney G, Morelli E, Morillas E, O'Connor R, Cruz-Pereira JS, Peterson VL, Rea K, Ritz NL, Sherwin E, Spichak S, Teichman EM, van de Wouw M, Ventura-Silva AP, Wallace-Fitzsimons SE, Hyland N, Clarke G, Dinan TG. The microbiota - gut - brain axis[J]. Physiol Rev, 2019, 99: 1877-2013.
[3] Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease [J]. Nat Rev Microbiol, 2021, 19: 55-71.
[4] Gubert C, Kong G, Renoir T, Hannan AJ. Exercise, diet and stress as modulators of gut microbiota: implications for neurodegenerative diseases [J]. Neurobiol Dis, 2020, 134: 104621.
[5] Kadowaki A, Quintana FJ. The gut - CNS axis in multiple sclerosis [J]. Trends Neurosci, 2020, 43: 622-634.
[6] Haase S, Haghikia A, Wilck N, Müller DN, Linker RA. Impacts of microbiome metabolites on immune regulation and autoimmunity [J]. Immunology, 2018, 154: 230-238.
[7] Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system[J]. Nat Rev Immunol, 2017, 17: 219-232.
[8] Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review [J]. Am J Med, 2020, 133: 1380-1390.
[9] Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis [J]. Nat Rev Neurol, 2017, 13: 25-36.
[10] Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L, Weiner HL. Alterations of the human gut microbiome in multiple sclerosis [J]. Nat Commun, 2016, 7: 12015.
[11] Zeng Q, Gong J, Liu X, Chen C, Sun X, Li H, Zhou Y, Cui C, Wang Y, Yang Y, Wu A, Shu Y, Hu X, Lu Z, Zheng SG, Qiu W, Lu Y. Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis [J]. Neurochem Int, 2019, 129: 104468.
[12] Chen H, Ma X, Liu Y, Ma L, Chen Z, Lin X, Si L, Ma X, Chen X. Gut microbiota interventions with clostridium butyricum and norfloxacin modulate immune response in experimental autoimmune encephalomyelitis mice[J]. Front Immunol, 2019, 10: 1662.
[13] Shahi SK, Freedman SN, Murra AC, Zarei K, Sompallae R, Gibson - Corley KN, Karandikar NJ, Murray JA, Mangalam AK. Prevotella histicola, a human gut commensal, is as potent as COPAXONE? in an animal model of multiple sclerosis[J]. Front Immunol, 2019, 10: 462.
[14] Kap YS, Bus - Spoor C, van Driel N, Dubbelaar ML, Grit C, Kooistra SM, Fagrouch ZC, Verschoor EJ, Bauer J, Eggen BJL, Harmsen HJM, Laman JD, 't Hart BA. Targeted diet modification reduces multiple sclerosis - like disease in adult marmoset monkeys from an outbred colony[J]. J Immunol, 2018, 201: 3229-3243.
[15] Bahr LS, Bock M, Liebscher D, Bellmann - Strobl J, Franz L, Prüß A, Schumann D, Piper SK, Kessler CS, Steckhan N, Michalsen A, Paul F, Mähler A. Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study[J]. Trials, 2020, 21: 3.
[16] Sonner JK, Keil M, Falk - Paulsen M, Mishra N, Rehman A, Kramer M, Deumelandt K, Röwe J, Sanghvi K, Wolf L, von Landenberg A, Wolff H, Bharti R, Oezen I, Lanz TV, Wanke F, Tang Y, Brandao I, Mohapatra SR, Epping L, Grill A, Röth R, Niesler B, Meuth SG, Opitz CA, Okun JG, Reinhardt C, Kurschus FC, Wick W, Bode HB, Rosenstiel P, Platten M. Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology[J]. Nat Commun, 2019, 10: 4877.
[17] Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, Kivisakk P, Vanande IP, Cook S, Gandhi R, Glanz B, Stankiewicz J, Weiner HL. Investigation of probiotics in multiple sclerosis[J]. Mult Scler, 2018, 24: 58-63.
[18] Libbey JE, Sanchez JM, Doty DJ, Sim JT, Cusick MF, Cox JE, Fischer KF, Round JL, Fujinami RS. Variations in diet cause alterations in microbiota and metabolites that follow changes in disease severity in a multiple sclerosis model [J]. Benef Microbes, 2018, 9: 495-513.
[19] Liu S, Rezende RM, Moreira TG, Tankou SK, Cox LM, Wu M, Song A, Dhang FH, Wei Z, Costamagna G, Weiner HL. Oral administration of miR - 30 d from feces of MS patients suppresses MS - like symptoms in mice by expanding akkermansia muciniphila[J]. Cell Host Microbe, 2019, 26: 779- 794.
[20] Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: understanding, treatment and innovative treatment prospect[J]. J Neuroimmunol, 2020, 348: 577387.
[21] Gong J, Qiu W, Zeng Q, Liu X, Sun X, Li H, Yang Y, Wu A, Bao J, Wang Y, Shu Y, Hu X, Bellanti JA, Zheng SG, Lu Y, Lu Z. Lack of short - chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: a Chinese pilot study[J]. Mult Scler, 2019, 25: 1316-1325.
[22] Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease[J]. Sci Rep, 2015, 5: 8096.
[23] Luu M, Pautz S, Kohl V, Singh R, Romero R, Lucas S, Hofmann J, Raifer H, Vachharajani N, Carrascosa LC, Lamp B, Nist A, Stiewe T, Shaul Y, Adhikary T, Zaiss MM, Lauth M, Steinhoff U, Visekruna A. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic - epigenetic crosstalk in lymphocytes[J]. Nat Commun, 2019, 10: 760.
[24] Pandit L, Cox LM, Malli C, D'Cunha A, Rooney T, Lokhande H, Willocq V, Saxena S, Chitnis T. Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4 [J]. Neurol Neuroimmunol Neuroinflamm, 2020, 8: e907.
[25] Zhang J, Xu YF, Wu L, Li HF, Wu ZY. Characteristic of gut microbiota in southeastern Chinese patients with neuromyelitis optica spectrum disorders[J]. Mult Scler Relat Disord, 2020, 44: 102217.
[26] Shi Z, Qiu Y, Wang J, Fang Y, Zhang Y, Chen H, Du Q, Zhao Z, Yan C, Yang M, Zhou H. Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: a cross sectional study[J]. J Neuroimmunol, 2020, 339: 577126.
[27] Rössling R, Prüss H. Apheresis in autoimmune encephalitis and autoimmune dementia[J]. J Clin Med, 2020, 9: 2683.
[28] Chen H, Chen Z, Shen L, Wu X, Ma X, Lin D, Zhang M, Ma X, Liu Y, Wang Z, Zhang Y, Kuang Z, Lu Z, Li X, Ma L, Lin X, Si L, Chen X. Fecal microbiota transplantation from patients with autoimmune encephalitis modulates Th17 response and relevant behaviors in mice[J]. Cell Death Discov, 2020, 6: 75.
[29] Gong X, Liu X, Li C, Chen C, Lin J, Li A, An D, Zhou D, Hong Z. Alterations in the human gut microbiome in anti - N - methyl - D - aspartate receptor encephalitis[J]. Ann Clin Transl Neurol, 2019, 6: 1771-1781.
[30] Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome[J]. Nature, 2012, 486: 207-214.
[31] Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, Liu Y, Cheng K, Zhou C, Wang H, Zhou X, Gui S, Perry SW, Wong ML, Licinio J, Wei H, Xie P. The gut microbiome from patients with schizophrenia modulates the glutamate - glutamine - GABA cycle and schizophrenia - relevant behaviors in mice[J]. Sci Adv, 2019, 5: eaau8317.
[32] Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies[J]. Lancet Neurol, 2015, 14: 1023-1036.
[33] Zheng P, Li Y, Wu J, Zhang H, Huang Y, Tan X, Pan J, Duan J, Liang W, Yin B, Deng F, Perry SW, Wong ML, Licinio J, Wei H, Yu G, Xie P. Perturbed microbial ecology in myasthenia gravis: evidence from the gut microbiome and fecal metabolome [J]. Adv Sci (Weinh), 2019, 6: 1901441.
[34] Tan X, Huang Y, Chai T, Zhao X, Li Y, Wu J, Zhang H, Duan J, Liang W, Yin B, Cheng K, Yu G, Zheng P, Xie P. Differential gut microbiota and fecal metabolites related with the clinical subtypes of myasthenia gravis[J]. Front Microbiol, 2020, 11: 564579.
[35] Rinaldi E, Consonni A, Cordiglieri C, Sacco G, Crasà C, Fontana A, Morelli L, Elli M, Mantegazza R, Baggi F. Therapeutic effect of bifidobacterium administration on experimental autoimmune myasthenia gravis in lewis rats[J]. Front Immunol, 2019, 10: 2949.
[36] Xiao J, Simard AR, Shi FD, Hao J. New strategies in the management of Guillain - Barre syndrome[J]. Clin Rev Allergy Immunol, 2014, 47: 274-288.
[37] Brooks PT, Brakel KA, Bell JA, Bejcek CE, Gilpin T, Brudvig JM, Mansfield LS. Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice [J]. Microbiome, 2017, 5: 92.
[38] Brooks PT, Bell JA, Bejcek CE, Malik A, Mansfield LS. An antibiotic depleted microbiome drives severe Campylobacter jejuni - mediated type 1/17 colitis, type 2 autoimmunity and neurologic sequelae in a mouse model[J]. J Neuroimmunol, 2019, 337: 577048.
[39] Kaakoush NO, Castaño - Rodríguez N, Mitchell HM, Man SM. Global epidemiology of campylobacter infection [J]. Clin Microbiol Rev, 2015, 28: 687-720. |